Letter: Tirzepatide in Type 1 Diabetic Obese Patient Using Hybrid Closed-Loop

Abstract

Get full access to this article

View all access options for this article.

References

Garg

, Kaur

, Renner

, et al. Cardiovascular and renal biomarkers in overweight and obese adults with type 1 diabetes treated with tirzepatide for 21 months. Diabetes Technol Ther, 2025; 27(3):152–160; doi: 10.1089/dia.2024.0481

Dejgaard

, Frandsen

, Kielgast

, et al. Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): A randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab, 2024; 26(11):4905–4915; doi: 10.1111/dom.15432

Pasqua

MR, Tsoukas MA, Kobayati A

, et al. Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: A double-blind, randomized, crossover trial. Nat Med, 2025; 31(4):1239–1245; doi: 10.1038/s41591-024-03463-z

, Li

, Staton

, et al. GLP-1 receptor agonist and SGLT2 inhibitor prescribing in people with type 1 diabetes. JAMA, 2024; 332(19):1667–1669; doi: 10.1001/jama.2024.18581

Corrao

, Pollicino

, Maggio

, et al. Tirzepatide against obesity and insulin resistance: Pathophysiological aspects and clinical evidence. Front Endocrinol (Lausanne), 2024; 15:1402583; doi: 10.3389/fendo.2024.1402583